Gary Leiserowitz, M.D., M.S.

Gary Scott Leiserowitz, M.D., M.S.

Specialties

Cancer

Gynecology Oncology

Obstetrics and Gynecology

Robotic Surgery

Surgery - Robotic

Title

  • Chair, Department of Obstetrics and Gynecology
  • Professor and Chief, Gynecologic Oncology and Obstetrics and Gynecology - Robotic Surgery
  • Fellowship Director, Gynecologic Oncology
  • Director, Surgical Services - Department of Obstetrics and Gynecology
  • Director, Women�s Cancer Care Program

Reviews

To see if Gary Scott Leiserowitz is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

4501 X Street, 2nd Floor
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

Additional Phone Numbers

Physician Referrals: 800-362-5566

Clinical Interests

Gary S. Leiserowitz and his colleagues in the Division of Gynecologic Oncology believe in patient-centered care that is anchored in the most current evidence-based medicine. He works closely with other physicians in medical oncology, radiation oncology and pathology to bring a multidisciplinary focus to each patient’s case.

His extensive surgical experience includes minimally invasive and robotic-assisted procedures for a variety of conditions. As a member and former director of the gynecologic oncology fellowship program at UC Davis, Leiserowitz is also helping train the next generation of specialists in cancers of the female reproductive system.

Division

Gynecologic Oncology

Center/Program Affiliation

Robotic Surgery Program
UC Davis Comprehensive Cancer Center

Education

M.D., University of Iowa College of Medicine, Iowa City IA 1981

M.S., Mayo Graduate School of Medicine, Rochester MN 1993

B.S., University of Iowa, Iowa City IA 1976

Internship: Family Medicine, Ventura County Medical Center, Ventura CA 1981-1982

Residency

Obstetrics and Gynecology, UC Davis Medical Center, Sacramento CA 1986-1988

Chief Resident - Obstetrics and Gynecology, UC Davis Medical Center, Sacramento CA 1988-1989

Family Medicine, Ventura County Medical Center, Ventura CA 1982-1984

Fellowships

Gynecologic Oncology, Mayo Clinic, Rochester MN 1990-1993

Board Certifications

American Board of Family Medicine,

American Board of Obstetrics and Gynecology, 2002

American Board of Obstetrics and Gynecology, Gynecologic Oncology, 2012

Professional Memberships

American College of Obstetrics and Gynecology

Council of University Chairs of Obstetrics and Gynecology

Society of Gynecologic Oncologists

Western Association of Gynecologic Oncologists

Honors and Awards

�Top Doctors � Sacramento,� 2016, 2017, 2018, 2019

Dean�s Team Award for Excellence � Clinical Care. Interstitial Brachytherapy for Gynecologic Cancers., 2016

�Best Doctors in America" 2003, 2005, 2013, 2015

2015 Roy M. Pitkin Award; established in 1998 to honor departments of obstetrics and gynecology that promote and demonstrate excellence in research. The winning article is: Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015;126:491�7., 2016

James F. Nolan Award for best clinical paper. 44th Annual WAGO meeting award: �Comparison of LAVH vs. TAH for Endometrial Cancer for Clinical Outcomes and Survival: A Population-Based Study�, 2014

Sacramento Super Doctors, 2011

Who's Who in Healthcare, 2011

Richard H. Oi, MD OB/GYN Excellence in Teaching Award, Resident Teaching Award, 2009

James F. Nolan Award for best clinical paper, 35th Annual WAGO meeting award, 2006

Select Recent Publications

Chen H, Gotimer K, De Souza C, Tepper CG, Karnezis AN, Leiserowitz GS, Chien J, Smith LH. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. Gynecol Oncol. 2020 Apr 3:S0090-8258(20)30251-1. PMID: 32253045.

Girda E, Huang EC, Leiserowitz GS, Smith LH. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707. PubMed PMID: 28683005.

Carney RP, Hazari S, Colquhoun M, Tran D, Hwang B, Mulligan MS, Bryers JD, Girda E, Leiserowitz GS, Smith ZJ, Lam KS. Multispectral optical tweezers for biochemical fingerprinting of CD9-positive exosome subpopulations. Anal Chem. 2017 Mar 27. PMID: 28345878.

Leiserowitz GS, Lin JF, Tergas AI, Cliby WA, Bristow RE. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. Int J Gynecol Cancer. 2017 Mar 22. PubMed PMID: 28328580.

Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. Obstet Gynecol. 2015 Sep;126(3):491-7.

Kim K, Ruhaak LR, Nguyen UT, Taylor SL, Dimapasoc L, Williams C, Stroble C, Ozcan S, Miyamoto S, Lebrilla CB, Leiserowitz GS. Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):611-21.

Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May;405(14):4953-8.

Hua S, Williams CC, Dimapasoc LM, Ro GS, Ozcan S, Miyamoto S, Lebrilla CB, An HJ, Leiserowitz GS. Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. J Chromatogr A. 2013 Mar 1;1279:58-67.

Cress RD, Bauer K, O'Malley CD, Kahn AR, Schymura MJ, Wike JM, Stewart SL, Leiserowitz GS. Surgical staging of early stage epithelial ovarian cancer: results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol. 2011 Apr;121(1):94-9.